An In Sitro Assay to Predict Primary Resistance to PD-1 Blockade.

Immune check point inhibition (ICI) is a paradigm shift in oncology, but most patients treated with ICI will not respond to treatment. Thus, the need for predictive biomarkers for ICI is high. Dubuisson and colleagues have now reported on a new functional assay that might accurately inform on ICI response.